Talis Biomedical Corporation (TLIS)

Market Cap	16.02M
Revenue (ttm)	2.13M
Net Income (ttm)	-62.01M
Shares Out	1.82M
EPS (ttm)	-34.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,782
Open	8.57
Previous Close	8.70
Day's Range	8.40 - 8.80
52-Week Range	4.35 - 9.32
Beta	1.74
Analysts	Strong Sell
Price Target	5.00 (-42.2%)
Earnings Date	May 9, 2024

About TLIS

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headq...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 12, 2021
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: TLIS

Financial Performance

In 2023, TLIS's revenue was $2.13 million, a decrease of -55.65% compared to the previous year's $4.81 million. Losses were -$62.01 million, -45.13% less than in 2022.

Analyst Forecast

According to one analyst, the rating for TLIS stock is "Strong Sell" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(-42.20% downside)

Analyst Consensus: Strong Sell